CV risk reduction with SGLT2 inhibitor consistent across age groups in type 2 diabetes

Results from sub-analyses of EMPA-REG OUTCOME trial showed risk reductions were consistent across age groups for CV outcomes, including CV death, with empagliflozin compared with placebo when added to standard of care in adults with type 2 diabetes and established CV disease.
In a separate analysis, empagliflozin also reduced risk for CV events consistently in groups divided by LDL cholesterol level [1].

Data presented at the ADA Scientific Sessions examined the effect of treatment with empagliflozin by age in the EMPA-REG OUTCOME trial. [1-3] Trial participants were grouped based on their age at baseline: under 65 years, from 65 to 74, and 75 years and older. Consistent reduction in the risk of CV death was seen independent of age groups. Further analysis demonstrated similar consistency by age group in reducing risk for hospitalisation for heart failure, as well as for the combination of hospitalisation for heart failure or CV death. Adverse events were consistent with the known safety profile of empagliflozin.

Furthermore, the reduction in risk for CV events did not differ among sub-groups of people in the EMPA-REG OUTCOME trial based on their LDL cholesterol levels at baseline (<70 mg/dL; 70-<85 mg/dL; 85-<100 mg/dL; 100-115 mg/dL; and >115 mg/dL). The risk reduction with empagliflozin was consistent across the LDL sub-groups (indicated by a lack of statistical interaction by sub-group) for the combination of CV death, non-fatal heart attack or non-fatal stroke, as well as for the individual outcomes of CV death, hospitalisation for heart failure and death from any cause.

Source: Press release Boehringer Ingelheim, June 12, 2016

1. Langslet, G., et al. Cardiovascular (CV) outcomes according to LDL cholesterol (LDL-C) levels in EMPA-REG OUTCOME. Poster No. 418-P. Presented at the American Diabetes Association (ADA) 76th Scientific Sessions^®. June 10 - 14, New Orleans, Louisiana, United States.
2. Ridderstråle, M., et al. Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG OUTCOME. Poster No. 1109-P. Presented at the American Diabetes Association (ADA) 76th Scientific Sessions^®. June 10 - 14, New Orleans, Louisiana, United States.
3. Monteiro, P., et al. Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG OUTCOME. Poster No. 1116-P. Presented at the American Diabetes Association (ADA) 76th Scientific Sessions^®. June 10 - 14, New Orleans, Louisiana, United States.